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Abstract
The immunological mechanisms explaining development of an allergy in some individuals
and not in others remain incompletely understood. Insect bite hypersensitivity (IBH) is a
common, seasonal, IgE-mediated, pruritic skin disorder that affects considerable propor-
tions of horses of different breeds, which is caused by bites of the insect Culicoides obsole-
tus (C. obsoletus). We investigated the allergen-specific immune status of individual horses
that had either been diagnosed to be healthy or to suffer of IBH. Following intradermal aller-
gen injection, skin biopsies were taken of IBH-affected and healthy ponies and cytokine ex-
pression was determined by RT-PCR. In addition, allergen-specific antibody titers were
measured and cytokine expression of in vitro stimulated, allergen-specific CD4 T-cells was
determined. 24 hrs after allergen injection, a significant increase in mRNA expression of the
type-2 cytokine IL-4 was observed in the skin of IBH-affected Shetland ponies. In the skin of
healthy ponies, however, an increase in IFNγmRNA expression was found. Analysis of al-
lergen-specific antibody titers revealed that all animals produced allergen-specific antibod-
ies, and allergen-specific stimulation of CD4 T-cells revealed a significant higher
percentage of IFNγ-expressing CD4 T-cells in healthy ponies compared to IBH-affected po-
nies. These data indicate that horses not affected by IBH, in contrast to the so far estab-
lished dogma, are not immunologically ignorant but have a Th1-skewed allergen-specific
immune response that appears to protect against IBH-associated symptoms. To our knowl-
edge this is the first demonstration of a natural situation, in which an allergen-specific im-
mune skewing is protective in an allergic disorder.
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Introduction
Following the seminal discovery by Mosmann and Coffman that CD4 T-cells can differentiate
into different subtypes [1], hypersensitivity reactions became associated with different CD4 T-
helper (Th) subtypes. Th1 cells, as characterized by the expression of the cytokine IFNγ, have
been associated with type IV hypersensitivity reactions, which are T-cell mediated, delayed
type hypersensitivity responses. Th2 cells, as characterized by the expression of the cytokines
IL-4, IL-5, and IL-13, have been associated with classical, allergic type-I hypersensitivity reac-
tions; reactions that are associated with an IgE-mediated degranulation of mast cells. Neverthe-
less, it rapidly was recognized that a more mixed reactions of both types of immune responses
persists in most allergic individuals. In mouse models, it was shown that the treatment of aller-
gic animals with type-1 inducing CpG-ODN can ameliorate disease symptoms [2]. However,
mainly due to a lack of a truly natural, experimental model systems, knowledge of how these
two types of immune responses develop in conjunction with each other during the immune re-
sponse to an allergen, and how these dynamic interactions contribute to, or prevent the devel-
opment of allergic disorders, is still largely lacking [3]. Most interestingly, even in a clinical
trial in which immune-stimulatory CpG-ODN sequences coupled to allergens were adminis-
tered, the treatment-induced amelioration of symptoms was not correlated with intracellular
levels of IL-4 or IFNγ in activated CD4T cells [4].
To determine how an underlying, allergen-specific immune skewing may contribute to the
development of allergies, we chose a natural, experimental model system in horses. Consider-
able proportions of horses of different breeds suffer from an IgE-mediated allergic reaction to
Culicoides spp., a disorder commonly called insect bite hypersensitivity (IBH) [5–7]. Diagnosis
of IBH is predominantly based on the assessment of clinical symptoms in the IBH season and a
positive skin test with Culicoides spp. extract. Culicoides-specific IgE titers are reported to be
higher in IBH-affected ponies compared to healthy ponies [8–11], and histology of IBH
lesional skin showed pronounced eosinophilia [12] and IgE- positive mast cells in acute
lesional IBH skin [13]. Therefore, IBH has generally been considered a type-I allergic hypersen-
sitivity reaction. Nevertheless, also an enhanced infiltration of CD4+ T cells and a pronounced
type-IV delayed type hypersensitivity component has been described in skin test responses
[14].
To our knowledge, no systematic, longitudinal studies have been performed so far that
would have given insight into the local immune response during an allergen-induced IBH chal-
lenge. To address this aspect of immune responsiveness, we challenged healthy and IBH sensi-
tive ponies by injection of C. obsoletus whole body extract into the skin and collected biopsies
at different time points thereafter. Our results revealed that IBH-affected ponies show a clear
IL-4 characterized type-2 skewing of the immune response upon intra-cutaneous allergen in-
jection. Moreover, contrary to general assumption, healthy ponies, were not immunologically
ignorant to Culicoides-specific antigens, but showed a type-1 skewed immune response charac-




Sixteen Shetland ponies were included in the study during the IBH off-season and 19 during
the IBH-season, which reflected winter and summer respectively. IBH-affected ponies (n = 10
and n = 8 respectively, age range 2–10 years) had each been diagnosed by a certified veterinari-
an and had a history of recurrent, seasonal, pruritic clinical signs of the skin at the mane and
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tail with remission in the off-season. Control ponies (n = 6 and n = 11, respectively, age range
4–15 years) were randomly selected from the same stables and had been diagnosed to have no
clinical signs or history of IBH. None of the ponies was treated with immunosuppressive drugs
prior to or during the experiments.
All animal experiments were approved by the Animal Ethics Committee of the University
of Utrecht.
C. obsoletus whole body extract preparation
Whole body extract (WBE) was prepared as previously described before [15]. In brief, whole
body extract (WBE) was prepared from about three hundred life female C. obsoletus insects,
which were frozen at -80°C. After crushing insects with a micro-pestle in 1ml of PBS contain-
ing protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA), samples were centrifuged
at 14 000 rpm for 10 min at 4°C. Supernatant was filtered, snap-frozen in liquid nitrogen and
stored at -80°C, until use as WBE.
Diagnostic skin test
In horses, it is a common and accepted practice to diagnostically relate allergen-induced swell-
ing to histamine-induced swelling and therefore all ponies were injected intra-dermally with
0.1 ml PBS (T = 0), 0.1 ml 1:1000 histamine solution (positive control) and 0.1 ml 1 mg/ml C.
obsoletusWBE. The developing swelling was then measured 30 min post injection. The relative
wheal diameter (RWD) was calculated by subtracting the average value of the histamine and
PBS wheal diameter from the corresponding C. obsoletus wheal diameter. RWD = C. obsoletus
WD—((histamine WD + PBSWD)/2).
Collection and processing of blood and skin samples
Prior to injection, blood was collected form each pony. For the determination of C. obsoletus-
specific antibody isotypes titers, serum was separated and stored at -20°C. Skin biopsies (4
mm) of WBE injection sites and controls were taken 5 min, 20 min and 24 hrs after allergen in-
jection, under local anesthesia with 2% lidocaine (B. Braun, AGMelsungen, Germany). Three
biopsies were taken per time point, whereby each site was separated far enough from the next
to prevent any influence from the one injection to the other. Of the three biopsies taken per
time point, two were snap-frozen in liquid nitrogen and stored at -80°C until used for RNA iso-
lation. The third skin biopsy was fixed in 4% neutral buffered formaldehyde and paraffin-em-
bedded for histopathology.
C. obsoletus-specific antibody titers
ELISA was performed and analyzed as described previously [15]. In brief, microtiter plates
were coated with 10 μg/ml C. obsoletus and incubated overnight at 4°C. After washing the
plates and blocking, diluted serum samples (1:5, 1:50 and 1:500) were added in duplicate. After
1.5 hrs, plates were washed and incubated for 1 hr with HRP-labeled, goat anti-horse isotype
specific antibodies: IgGa (AAI35P), IgGb (AAI36P), IgGc (AAI37P) or IgG(T) (AAI38P)
(AbD Serotec, Düsseldorf, Germany) diluted 1:1000 in casein buffer. The microtiter plates
were washed with PBS-Tween and developed with tetramethylbenzidine at RT. The reaction
was stopped with a 1% HCL solution. Absorbance was measured with a SpectraMax M5 multi-
mode microplate reader (Molecular Devices, Berkshire, UK) at a wavelength of 450 nm cor-
rected for the OD measured at 650 nm. The values used for further analysis were calculated by
subtracting the OD450 of the serum-free control from the OD450 of serum samples.
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Histological examination of skin samples
Paraffin-embedded biopsies were cut in 4 μm sections and stained with either haematoxylin-
eosin (HE) for routine histopathology or toluidine blue (TB) for mast cell analysis. Sections
were graded according to a semi-quantitative grading system (0 = absent, 1 = minimal,
2 = mild, 3 = moderate, 4 = severe) as previously described [12]. All HE slides were analyzed
microscopically in a blinded fashion towards the experimental grouping of biopsies. Total
number of mast cells was determined by counting these cells in three representative fields per
slide at 400 x magnification.
mRNA expression in skin biopsies
Snap-frozen skin samples were cut and homogenized with beads for 30 min at a frequency 25/s
in 0.5 ml TRIzol reagent (Invitrogen, Breda, NL) using a Mixer Mill 301 (Retsch Verder NV,
Vleuten, NL). Next 0.1 ml 100% chloroform was added to each sample and incubated at RT for
3 minutes. A water-phase was obtained by centrifuging 15 min at 14000 rpm at 4°C. The
mRNA was extracted from the water-phase using an RNeasy kit (Qiagen, Venlo, NL) according
to the manufacturer’s specification. The mRNA concentrations were measured with a Nano-
drop ND-1000 (Thermo Scientific, Etten-Leur, NL). A concentration of 1 μg total mRNA was
used to produce cDNA with an iScript cDNA Synthesis Kit (Bio-Rad laboratories, Veenendaal,
NL) according to the manufacturer’s instructions.
QPCR was performed as described previously [12]. All probes were designed with Primer3
(version 0.4.0); for details see S1 Table. Relative expression for each gene was calculated by the
Pfaffl method [16] using the housekeeping gene 18s ribosomal RNA (18s rRNA) as a reference.
In vitro differentiation of monocyte-derived dendritic cells
Monocytes were isolated from PBMC using mouse anti-human CD14 (biG 10, Biometec) and
anti-mouse IgG microbeads using an LS column (Miltenyi Biotec) according to the manufac-
turers’ specifications. Cells were then differentiated for two days in the presence of purified, E.
coli expressed recombinant horse IL-4 (50 ng/ml) and horse GM-CSF (50 ng/ml). After 2 days,
medium was refreshed with new IL-4 and GM-CSF. The culture was maintained for an addi-
tional 3 days prior to antigen exposure. Differentiation and maturation was examined by FACS
analysis using mouse anti-human CD206 (3.29B1.10, Beckman Coulter) and mouse anti-
human CD86 (IT2.2, Biolegend), and their respective isotype controls.
Antigen-specific T-cell stimulation
PBMC were stimulated with 10 μg/ml WBE or left untreated (mock). After 2 days, medium
was refreshed with medium containing 2 ng/ml recombinant equine IL-2 (Kingfisher Biotech).
Three days later, cells were harvested and mixed with matured autologous monocyte derived
DC that had been activated for 24 hrs with 1 μg/ml LPS either in the presence or absence of
10 μg/ml WBE. Cells were then incubated for 6 hrs in the presence of 5 μMmonensin (Sigma).
Cells were then stained for CD3 and CD4 using the mouse anti-equine CD4 (clone CVS4) and
intracellularly with mouse anti-bovine IFNγ (CC302, MCA1783F, AbD Serotec), and mouse
anti-equine IL-4 Alexa 647 (12H8). Cells were analyzed by flow cytometry and data analyzed
using FlowJo software (Tree Star).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4.00 (Graphpad Software, San Diego,
CA). To compare unpaired samples form IBH-affected ponies with those from healthy ponies,
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Mann–Whitney U test (+) was used. To compare paired data, non-parametric, paired Wil-
coxon Signed-Rank Test was used. Results were considered significant when p0.05.
Results
Increased influx of leucocytes in animals suffering from IBH
To investigate the allergen-specific immune balance in the skin of ponies that either suffered
from IBH or had been diagnosed to be healthy (Fig 1A), biopsies were taken at different time
points following C. obsoletus allergen injection in the skin. In previous studies, we had found
an overall, basal activation of the immune system in the skin of horses in summer [12]. To as-
certain maximal detection of allergen-specific immune responses in comparison to basal im-
mune activation in the skin, all samples were collected during winter, when Culicoides spp. are
absent. Histological analysis of the skin following allergen injection was performed using
H&E-stained slides from 10 IBH-affected and 6 healthy ponies. Slides were graded by a certi-
fied expert, who was blinded for the experimental set-up. In none of the samples, signs of
acanthosis or hyperkeratosis could be detected, indicating that the biopsy sites all represent
acute lesions (S2 Table). As shown in Fig 1B, both healthy and IBH-affected ponies showed an
increased lymphocyte influx into the skin upon allergen-injection over time. Influx into the
skin of IBH-affected animals was significantly stronger than that into the skin of unaffected an-
imals (Fig 1B). Eosinophilic granulocytes were found predominantly in the middle dermis of
the skin, and consistently more eosinophils were found in the skin of IBH-affected than in the
skin of healthy ponies (S2 Table).
Mast cells have been shown before to play an important role in the immune-pathogenesis of
IBH [13,17]. As shown in Fig 1C, also the number of mast cells in the skin of IBH-affected ani-
mals was significantly higher than that in the skin of unaffected animals. Frequency of mast
cells in the skin following injection stayed consistent over time, in both groups, suggesting that
there is no substantial allergen injection-induced efflux of mast cells into the draining lymph
nodes [18].
In contrast to mast cells, however, T-cells appeared to be emigrating from the skin. mRNA
expression of CD3z, a T cell marker, in snap-frozen skin biopsies declined in the skin of all
treated animals, but was most pronounced in the skin of IBH-affected animals (P = 0.0391)
(Fig 1D). MIP1α, a chemokine and activation marker, however, showed the direct opposite de-
velopment. In all animals MIP1αmRNA expression was up-regulated 24 hrs after allergen in-
jection, most pronounced in the skin of IBH-affected animals (P = 0.0039) (Fig 1E). MIP1α is
expressed by a wide range of different activated leukocytes, such as macrophages and activated
T-cells. Expression of MIP1α was most pronounced 24 hrs after allergen injection. It can be as-
sumed that most of the injected allergen will have been taken up and been processed at that
time point. Therefore these data suggest that the main source of MIP1α at the site of injection
must have been cells belonging to the adaptive immune response that were reacting to pro-
cessed epitopes presented by local antigen presenting cells. Such data further suggest that un-
specifically activated by-stander T-cells may at that time point have emigrated the site of in-
flammation, while allergen-specific T-cells have immigrated and have become activated.
IBH-affected animals have a type 2-biased immune response, while
unaffected animals have a type-1 biased immune response
To analyze the immune response following allergen injection in the skin in more detail, we as-
sessed cytokine expression in the biospies taken at different time points after injection. We
found the Th2 cytokine marker, IL-4, significantly (P = 0.0039) upregulated 24 hrs after
First Demonstration of a Protective Allergen-Specific Immune Skewing
PLOS ONE | DOI:10.1371/journal.pone.0122090 April 22, 2015 5 / 12
allergen injection. The expression was significantly (P<0.0001) higher in the skin of IBH-sensi-
tive than in the skin of unaffected animals (Fig 2B). Also IL-5, another Th2 cytokine marker,
showed a significant (P = 0.0137) upregulation in IBH skin 24 hrs after allergen injection (data
not shown). In contrast to IBH-sensitive animals, in the skin of healthy animals the Th1 cyto-
kine IFNγ was significantly (P = 0.0313) upregulated 24 hrs post injection (Fig 2A). In effect,
the balance of these two cytokines was substantially shifted towards an IFNγ -dominated re-
sponse in healthy animals, while IL-4 was more prominent in animals with IBH (Fig 2C).
Other cytokines, such as IL-10, did not show any up- or down-regulation between the different
time points (data not shown). The expression of FoxP3, a transcription factor specific for regu-
latory T-cells, did not differ between time points; nor was it different between the skin of
healthy and IBH-sensitive animals (data not shown).
Fig 1. Delayed-type hypersensitivity responses in ponies following allergen injection in the skin. Immune reactions of 6 healthy (light bars) and 10
IBH-sensitive animals (dark bars) to allergen injection in winter was determined at the site of injection at different time points after injection. A) relative skin
swelling in animals, 30 min following C. obsoletusWBE compared to histamine injection; B) total histological score of the skin;C) number of mast cells;D)
total CD3 mRNA expression; E) total MIP1αmRNA expression. Bars represent average +SEM; dots represent individual animals.
doi:10.1371/journal.pone.0122090.g001
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Taken together, these data show that ponies sensitive to IBH have a strong type-2 biased im-
mune response, while animals protected against IBH-associated pathology show a bias towards
a type-1 immune response 24 hrs after allergen injection.
Healthy ponies have Culicoides-specific antibody titers similar to IBH-
affected animals
To determine whether both IBH-sensitive as well as healthy ponies may have developed anti-
gen-specific immune responses against C. obsoletus antigens, we measured C. obsoletus-specific
IgE, IgGa, IgGb, IgGc and IgG(T) antibody levels in the blood of the animals in the off-season.
As shown in Fig 3, all animals, whether sensitive to IBH or not, had clearly detectable levels of
C. obsoletus-specific antibodies. As described before [10], the average C. obsoletus-specific IgE
serum level was elevated for IBH-sensitive compared to healthy animals (Fig 3), and significant
differences between IBH-sensitive and healthy animals were measured for C. obsoletus-specific
IgGa antibodies (P = 0.042), an isotype that correlates with the human IgG1 and is associated
with type-2 immune responses in horses [19]. No substantial differences, however, were found
for C. obsoletus-specific IgGb, IgGc and IgG(T) antibodies in serum between IBH and healthy
ponies (Fig 3).
These data show that all ponies have been exposed to allergens and that all animals have de-
veloped C. obsoletus-specific antibody responses.
Allergic animals have a Th2-biased allergen-specific immune response,
while protected animals have a Th1-biased response
To determine, whether the above-described bias in immune responses is reflected in the under-
lying allergen-specific CD4 T-helper cell differentiation, we determined the allergen-specific T-
Fig 2. Type-1 immune response skewing in the skin of healthy ponies following allergen injection.Cytokine expression at the site of injection, 24 hrs
after allergen injection, was determined by qRT-PCR. A) IFNγ andB) IL4 mRNA expression as ratio to 18S; C) ratio IFNγ / IL4 expression. Bars represent
average +SEM; n = 6 and n = 10, for healthy and IBH-sensitive animals, respectively; dots represent individual animals.
doi:10.1371/journal.pone.0122090.g002
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cell response in ponies. To this end, CD4 T-cells were isolated from the blood of ponies in sum-
mer during the allergy season. Isolated CD4 T-cells were then in vitro expanded by PBMC ex-
posed to allergen. Expanded allergen-specific CD4 T-cells were then re-stimulated with
allergen-exposed monocyte derived dendritic cells (DC) and cytokine expression was deter-
mined by intracellular cytokine staining. Background activation was determined by activation
of expanded T-cells by DC that had not been exposed to allergen. As shown in Fig 4, CD4 T-
cells expanded from healthy horses was significantly (P = 0,0058) higher in frequency than
IFNγ-producing allergen-specific CD4 T-cells from animals that suffered from IBH. Despite
the fact that healthy horses had also elevated IL4 responses, the ratio of IFNγ- versus IL4-pro-
ducing T-cells was in comparison to IBH affected animals substantially skewed towards IFNγ-
producing cells in healthy animals (Fig 4D).
Taken together, these data indicate that an underlying Th1 bias of the allergen-specific im-
mune response correlates with a protection of animals from the allergen-induced IBH-
associated pathology.
Discussion
Allergies are wide spread immunological disorders affecting a considerable proportion of the
populations. A complex interaction of genetic as well as environmental factors determines
whether an allergen-exposed individual becomes allergic or not. Generally, it is assumed that
individuals either react with an IgE-associated immune response or remain immunological
Fig 3. Healthy horses have allergen-specific serum antibodies. Allergen-specific antibody titers, for different isotypes, were determined in the serum of
healthy (dark bars) and IBH-sensitive animals (dark bars) by ELISA. Bars represent average +SEM; n = 6 and n = 10, for healthy and IBH-sensitive animals,
respectively; dots represent individual animals.
doi:10.1371/journal.pone.0122090.g003
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ignorant or tolerant upon exposure to the allergen. Moreover, is it assumed that in healthy in-
dividuals mainly cells that generally are involved in the induction of peripheral tolerance, such
as regulatory T-cells, induce tolerance also against allergens. Nevertheless, it remains still large-
ly unknown why such an immunological tolerance is induced in non-allergic individuals but
not in allergic individuals.
IBH is an IgE-mediated, naturally occurring allergic skin disease in horses caused by bites of
the insect, Culicoides spp.. IBH is affecting horse breeds differently and within affected breeds
variable fractions of local horse populations suffer from it [20]. IBH therefore appeared a high-
ly attractive model system to determine, why some animals that were exposed to the allergen
developed IBH, while others remained unaffected. To address the underlying mechanism that
determines why some animals are affected by IBH and others are not, we injected into animals
known to be affected by IBH, as well as in animals known to be not affected by IBH, whole
body extracts of Culicoides spp.—a method known to reliably reflect naturally evoked hyper-
sensitivity reactions in the skin [15]. Our data show that an underlying allergen-specific Th1
immune response correlated with protection, while an underlying allergen-specific Th2 im-
mune response led to the development of IBH. Thus, in contrast to general consensus, healthy
animals were not tolerant to the allergen, but responded in a non-pathogenic way to exposure.
In recent years, clinical studies in patients suffering from a number of different types of al-
lergies, such as allergies to cow’s milk [21], bee venom [22] or birch pollen [23], have shown
that an amelioration of symptoms and the induction of tolerance in allergic individuals is asso-
ciated with an increase of allergen-specific IgG4 antibodies. These antibodies compete with the
existing allergen-specific IgE antibodies for the allergen and thereby prevent the degranulation
of mast cells [24]. This shift away from IgE to IgG4 antibodies is supposed to be mediated by
IL-10 producing T-cells with regulatory function [24]. In this context, it is interesting to men-
tion that the group of Marti described an increased frequency of CD25high allergen-specific
FoxP3-expressing regulatory T-cells in healthy horses. The expression of FoxP3 was signifi-
cantly higher in regulatory T-cells derived from healthy than in cells derived from IBH-affected
horses, when in vitro stimulated by allergen [25].
The suppressive capacity of FoxP3-expressing regulatory T-cells in vivo is influenced by
mast cells [26, 27]. While the activation of mast cells enhances the suppressive capacity of local
Fig 4. Increased frequencies of allergen-specific Th1 cells in healthy compared to IBH-affected ponies. Allergen-specific CD4 T-cells were in vitro
expanded in summer from PBMC of 11 healthy and 8 IBH-affected animals, by stimulation with WBE. Cytokine expression of expanded CD4 T-cells was then
determined by exposure to monocyte-derived DCs in the presence or absence of allergen.A) representative FACS blot;B) IFNγ- andC) IL4 CD4 T-cells;D)
ratio IFNγ/ IL4 CD4 T-cells. Bars represent average +SEM; dots represent individual animals.
doi:10.1371/journal.pone.0122090.g004
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regulatory T-cell populations [26, 27], diminishes IgE-crosslinking induced degranulation of
mast cells the suppressive capacity of regulatory T-cells [28]. This effect is most likely mediated
via the local secretion of histamine [29]. In line with these finding, it was recently demonstrate
in a peanut-allergy model that mast cell-derived IL-4 contributes to the priming of allergen-
specific Th2 cell responses, while IgE activated mast cells impaired regulatory T-cell induction
[30]. Under allergic situations either IgE blockade or inhibition of mast cell signaling promoted
regulatory T-cell induction and restored regulatory T-cell versus Th2 cell balance. This balance
ultimately led to immune tolerance [30]. Similarly, a recent study using CpG treatment in a
chronic mouse lung inflammation model [31], demonstrated that the treatment-induced ame-
lioration of disease was less dependent on the induction of IFNγ expression but was more asso-
ciated with an enhanced regulatory T-cell response.
In line with these findings, we would—based on the data presented here—suggest a scenario
in which individuals that do not suffer from an allergic reaction may in first instance not be ig-
norant to an allergen, but develop a type-1 skewed allergen-specific immune response. In those
individuals that react with a type-1 biased allergen-specific immune response, regulatory T-cell
populations can suppress local allergic immune responses and induce allergen-specific immune
tolerance. Those individuals, however, who react with a type-2 biased immune response, aller-
gen-specific IgE crosslinking may induce degranulation of basophils and mast cells, which ren-
ders the local regulatory T-cell population non-functional. This may allow the local
inflammation to perpetuate itself, finally leading to the observed allergen-specific epitope
spreading and allergen-induced immunopathology. To test such a hypothesis, further research
should establish whether these two independent observations in horses, i.e. of differential im-
mune bias of IBH-sensitive and unaffected animals as described here, and the enhanced regula-
tory function of FoxP3 expressing regulatory T-cells in unaffected animals [25], are connected
with each other via an IgE and mast cell degranulation mediated mechanism.
Thus, taken together, our data cannot fully explain why some individuals react with a type-2
immune response to allergens in the first place. Nevertheless, our data suggest a novel way of
how to prevent the development of allergic diseases, for instance in individuals in danger of de-
veloping occupational allergic diseases. Such persons could, for instance, be immunized prior
to exposure to the allergen in a way that skews the allergen-specific immune response towards
a type-1 immune response. Further, should a therapeutic inhibition of mast cell degranulation
as well as of type-2 immune responses, accompanied by the induction of allergen-specific type-
1 biased allergen-specific immune responses, ameliorate symptoms of allergic individuals and
protect treated individuals from developing allergies. Our data further suggest that the natural
occurring allergic immune response of horses to Culicoides obsoletus-derived allergens could
be a valuable model system to test such novel therapeutic approaches; in particular so, since it
is well established that the immune response to Culicoides allergens in horses at the T cell level
closely resembles those in human allergies [32].
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